Drugs / AM003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06258330 | Jun 2022 → Jul 2024 | cancer | Aummune Ltd. | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-05-28 | Aummune Ltd. | Aummune’s Poster at ASCO 2024 to Highlight Ongoing Phase 1 Trial for AM003 aummune.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AM003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06258330 ↗ |
| Modality | Aptamer | “Bispecific Personalized Aptamer for intratumoral administration” NCT06258330 ↗ |